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MYC regulates fatty acid metabolism through a multigenic
program in claudin-low triple negative breast cancer
Jessica C. Casciano1, Caroline Perry1,2, Adam J. Cohen-Nowak1, Katelyn D. Miller1, Johan Vande Voorde3, Qifeng Zhang4,
Susan Chalmers5, Mairi E. Sandison5,6, Qin Liu1, Ann Hedley3, Tony McBryan3,7, Hsin-Yao Tang1, Nicole Gorman1, Thomas Beer1,
David W. Speicher1, Peter D. Adams8, Xuefeng Liu9, Richard Schlegel9, John G. McCarron5, Michael J. O. Wakelam4, Eyal Gottlieb3,10,
Andrew V. Kossenkov1 and Zachary T. Schug1
BACKGROUND: Recent studies have suggested that fatty acid oxidation (FAO) is a key metabolic pathway for the growth of triple
negative breast cancers (TNBCs), particularly those that have high expression of MYC. However, the underlying mechanism by
which MYC promotes FAO remains poorly understood.
METHODS: We used a combination of metabolomics, transcriptomics, bioinformatics, and microscopy to elucidate a potential
mechanism by which MYC regulates FAO in TNBC.
RESULTS: We propose that MYC induces a multigenic program that involves changes in intracellular calcium signalling and fatty
acid metabolism. We determined key roles for fatty acid transporters (CD36), lipases (LPL), and kinases (PDGFRB, CAMKK2, and
AMPK) that each contribute to promoting FAO in human mammary epithelial cells that express oncogenic levels of MYC.
Bioinformatic analysis further showed that this multigenic program is highly expressed and predicts poor survival in the claudin-low
molecular subtype of TNBC, but not other subtypes of TNBCs, suggesting that efforts to target FAO in the clinic may best serve
claudin-low TNBC patients.
CONCLUSION: We identified critical pieces of the FAO machinery that have the potential to be targeted for improved treatment of
patients with TNBC, especially the claudin-low molecular subtype.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0711-3
BACKGROUND
A recent study analysed the copy number and gene expression
changes in over 2000 breast tumours.1,2 One of the most
commonly and highly amplified genes in breast cancer is
MYC.1,3 MYC is a transcription factor that activates genes involved
in cell cycle regulation, cell growth, protein synthesis, mitochon-
drial function, and metabolism. MYC amplification occurs in ~25%
of all breast cancers and occurs more frequently in triple negative
breast cancer (TNBC) (up to 50%).4,5 MYC gene amplification is
associated with risk of relapse, poor prognosis, and death.6,7
MYC is a known regulator of metabolic reprogramming in
cancer.8,9 A recent study reported that TNBC cells with high
expression of MYC have high rates of fatty acid β-oxidation
(FAO).10 They further demonstrated that pharmacological inhibi-
tion of FAO with etomoxir impairs the growth of TNBC patient-
derived xenografts that have high MYC expression but not those
with low MYC expression, suggesting that targeting FAO may be a
viable treatment option for TNBC patients with high expression of
MYC.10 Unfortunately, the safety of etomoxir has been called into
question during clinical trials due to reports of liver toxicity and a
recent study showed that etomoxir can cause severe oxidative
stress in an off-target (non-CPT1A) dependent manner.11,12 There
is therefore unmet need for better, safer inhibitors of FAO. Other
targets associated with FAO have emerged more recently. For
instance, FAO has been shown to promote SRC activation and
metastasis in TNBC,13 while a separate study showed that CUB-
domain containing protein 1 (CDCP1) inhibits acyl-CoA synthe-
tases which then stimulates FAO in TNBC cell lines.14 However, the
role of CDCP1 in breast is controversial with conflicting
reports.15,16
The goal of our study was not to further prove the importance
of FAO in TNBC, but to elucidate the mechanistic link between
MYC and the activation of FAO and to identify new actionable
targets for blocking FAO in TNBC. We used human mammary
epithelial (HME) cells that express oncogenic levels of MYC as a
model system to cleanly delineate how MYC leads to enhanced
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FAO. Our results indicate that MYC alters calcium (Ca2+) signalling
that then promotes FAO by activating a Ca2+-CAMKK2-AMPK
signalling axis. We also identified an important role for fatty acid
transporter CD36, which mediates fatty acid uptake in TNBC. MYC
HME cells exhibited a 10-fold increase in cell migration compared
to isogenic cell lines expressing telomerase reverse transcriptase
(TERT) or HER2. The migration of MYC HME cells could be inhibited
by targeting CD36, CAMKK2, or FAO suggesting that uptake and
oxidation of fatty acids may be an important metabolic pathway
for supporting the energy demanding process of cell migration.
We find that CD36 and other fatty acid metabolism genes (i.e. LPL,
PDK4, FABP4) are highly co-expressed in TNBC, particularly in the
claudin-low subtype of TNBC where their high expression predicts
poor survival. Collectively, our studies helped to identify targets
that could be considered as new options for blocking FAO in TNBC
and suggests that targeting FAO may be most beneficial for
claudin-low TNBC patients.
METHODS
Cell culture, siRNA transfection, and lentiviral transduction
HME cells were cultured in 1× HMEC Basal Serum-Free Medium
(Thermo Fisher Scientific) supplemented with the HMEC Supple-
ment Kit (Thermo Fisher Scientific) and 1× penicillin–streptomycin
(Corning). MDA-MB-468 (ATCC), T47D (ATCC), BT474 (ATCC), MDA-
MB-231 (ATCC), Cal120 (DSMZ), Cal51 (DSMZ), BT549 (ATCC) cells
were cultured in 1× DMEM/F-12 50/50 supplemented with 10%
foetal bovine serum (FBS) (Life Technologies) and 1×
penicillin–streptomycin. Hs578t (ATCC) cells were cultured in 1×
DMEM/F-12 50/50 supplemented with 0.01 mg/ml bovine insulin
(Sigma), 10% FBS, and 1× penicillin–streptomycin. SUM159PT
(Asterand Bioscience) cells were cultured in 1× DMEM/F-12 50/
50 supplemented with 5% FBS, hydrocortisone (1 μg/ml), and
human insulin (5 μg/ml). siRNA transfections were performed by
reverse transfection using RNAiMAX. All siRNAs were obtained
from Qiagen and used as pools of four individual siRNAs. MYC
+pTRIPZ, MYC+shCD36#2, and MYC+shCD36#3 were generated
using lentivirus produced by HEK293T cells transfected (Lipofec-
tamine 2000) with psPAX2, pVSV-G, and the corresponding pTRIPZ
vector (GE Healthcare). MYC HME cell pools were selected using
puromycin. Doxycycline (0.5 μg/ml) was used to induce transcrip-
tion of shRNAs.
Western blotting
Cells were lysed in 1× Bolt LDS Sample Buffer (Life Technologies)
supplemented with 50 mM dithiothreitol (DTT). Lysates were
heated at 95 °C for 5 min and then centrifuged at 10,000×g for
10min. Lysates were then resolved using Bolt 4–12% Bis-Tris Plus
precast polyacrylamide gels (Life Technologies) for 30 min at 200 V
and blotted onto nitrocellulose membranes for 1 h at 10 V using
the Mini Blot Module transfer system (Life Technologies). The blots
were then blocked using 5% milk in Tris buffered saline solution
with tween (TBST) for 1 h at room temperature. Blots were
incubated with primary antibodies overnight at 4 °C. Primary
antibodies were used at a 1:1000 dilution in 1% bovine serum
albumin (BSA) and 0.05% sodium azide in TBST. Antibodies were
purchased from the following vendors: Actin (Abcam #8226), TERT,
HER2 (Cell Signaling #4290), MYC (Cell Signaling #5605), tubulin
(Sigma HPA043640), ER (Cell Signaling #8644), PR (Cell Signaling
#8757), EGFR (Cell Signaling #4267), AMPK (Cell Signaling #2532),
P-AMPK (Cell Signaling #2535), P-ACC (Cell Signaling #3661),
CAMKK2 (Santa Cruz #100364 and Abnova #H00010645), CDH1
(Cell Signaling #5296), and PDGFRB (Cell Signaling #3169).
Secondary antibodies were purchased from Li-Cor Biosciences
(goat anti-mouse #926-32210 and donkey anti-rabbit #926-68073)
and diluted to a 1:10,000 solution in TBST. Incubation with the
secondary antibody occurred at room temperature for 1 h. Blots
were imaged using a Li-Cor Odyssey infrared imager.
Quantitative PCR (qRT-PCR)
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and
reverse transcribed using the SuperScript IV VILO Master Mix (Life
Technologies). cDNA was amplified via the Fast SYBR Green
Master Mix (Life Technologies) using the ABI 7500 Fast qPCR
system (Thermo Fisher Scientific). Results were analysed using the
ABI 7500 software v2.0.6. Relative expression levels of target genes
were determined by normalisation to the β-actin gene using the
ΔΔCt method.
For quantification of mitochondrial DNA, mtDNA was isolated
from HME cells using the Mitochondrial DNA Isolation Kit (Abcam;
ab65321). Genomic DNA (gDNA) was isolated from HME cells
using a gDNA purification kit (Thermo Scientific). qPCR was
performed using the ABI 7500 Fast qPCR system (Thermo Fisher
Scientific) and results were analysed using the ABI 7500 software
v2.0.6. Relative expression levels of the mitochondrial genes
tRNALeu(UUR) and 16S rRNA were determined by normalisation to
the nuclear gene β2-microglobulin using the ΔΔCt method as
previously described.17,18
Flow cytometry
For MitoTracker Green staining HME cells were pelleted, washed
with ice-cold PBS, and resuspended in 1× HME cells Basal Serum-
Free Medium (Thermo Fisher Scientific) and incubated with 20 nM
MitoTracker Green FM (Thermo Fisher Scientific). Cells were then
stained with PI (Alfa Aesar). Cells were sorted on a FACSCalibur
(Becton-Dickinson) flow cytometer using CellQuest software. Cells
were first sorted for PI staining; PI-positive cells were excluded
from analysis. Cells were then sorted for MitoTracker Green
staining. The geometric mean of MitoTracker Green intensity was
used for analysis. Figure presentation was completed using FlowJo
software.
For cell death/cell cycle analysis via PI staining, HME cells were
treated with 10 µM STO-609 or 150 µM Etomoxir for 48 h. Cells and
cell medium were pelleted, washed with ice-cold PBS and then
fixed with ice-cold 70% ethanol. Cells were washed once more
with ice-cold PBS prior to RNA digestion. Cells were then stained
with PI. Cells were sorted on a FACSCalibur (Becton-Dickinson)
flow cytometer using CellQuest software. Cells were first sorted for
PI staining and a cell cycle profile was created based on PI
fluorescence intensity. The percentage of cells in each segment of
the cell cycle profile (Sub-G1, G0/G1, S, or G2/M) was used for
analysis. Data analysis and figure presentation was completed
using FlowJo software.
For cell surface receptor expression analysis, cells were
detached using cell dissociation buffer (Thermo Fisher Scientific)
and washed in ice-cold PBS. Cells were washed in stain buffer (PBS
and 5% BSA). Cells were incubated for 30min on ice in primary
antibody CD36 (Epitomics #S1249; now discontinued) or GFP
(Clontech) and then washed in stain buffer. For CD36 and GFP
staining, Alexa Fluor 488 was added for 15 min on ice before
washing the cells in stain buffer. Cells were analysed on a
FACSCalibur (Becton-Dickinson) flow cytometer using CellQuest
software.
Confocal microscopy
MYC and TERT HME cells were grown in 6-well plates on glass
coverslips. Cells were washed with PBS and fixed in 4%
paraformaldehyde at room temperature. Coverslips were washed
in PBS and blocked with 10% FBS and incubated overnight with
anti-human CD36 (Epitomics #S1249; now discontinued) in 5%
BSA. Coverslips were incubated with Alexa Fluor 488 anti-mouse
IgG (Molecular Probes) in 5% BSA, washed in PBS and mounted in
immunofluorescence mounting medium containing DAPI (Vecta-
shield; Vector Laboratories, Servion, Switzerland). Specimens were
analysed using a confocal microscope (Leica SP2 (DMIRBE) laser
scanning confocal with Leica SP2 software) equipped with a 63×/
1.32.ph3 oil HCX PL APO lens (Leica, Milton Keynes, UK).
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Time-lapse imaging of fatty acid uptake
HME cells were plated on thin layer matrigel-coated glass 6-well
plates and treated with 0.5× Loading Buffer containing BODIPY-
labelled dodecanoic acid. Loading Buffer was prepared according
to the manufacturer’s instructions for the QBT Fatty Acid Uptake
Assay Kit (Molecular Devices). Briefly, the contents of one vial
containing BODIPY-labelled dodecanoic acid was dissolved in
10ml of 1× HMEC Basal Serum-Free Medium (Thermo Fisher
Scientific) + 0.2% fatty acid-free BSA (Sigma) to create 1× Loading
Buffer. HME cells were imaged for 6 h using a Nikon TE300
Automated Inverted Microscope equipped with a 40× objective
and a Hamamatsu ORCA camera. Images were captured every
5 min with a 400-ms exposure. For time-lapse imaging of STO-609-
(10 μM) and etomoxir (40 μM)-treated cells, drugs were added
simultaneously with 0.5× Loading Buffer. Fluorescence intensity
and cell migration was tracked and calculated for individual cells
using the Nikon NIS Elements software, version 4.2.
Carbon-13 stable isotope tracing experiments and metabolomics
All metabolomic and lipidomic studies were performed as
previously described with minor differences.19,20 All metabolomic
experiments were performed in serum-like modified Eagle’s
medium (SMEM), the formula of which has been previously
described.19,21 SMEM contains 54 different nutrients that are
found in the bloodstream at concentrations that are physiologi-
cally relevant to humans. SMEM was supplemented with the
HMEC Supplement Kit from Invitrogen (Life Technologies). Cells
were incubated in uniformly labelled 13C-palmitate (0.05 mM), 13C-
glucose (5.5 mM), or 13C-glutamine (0.65 mM) for 30 min, 4 h, or
8 h as indicated in the figure legends. For intracellular extracts,
after incubation, the SMEM medium was aspirated and cells were
washed once in ice-cold PBS. Metabolites were extracted by
adding a solution of methanol/acetonitrile/water (5:3:2) to the
well. Plates were incubated at 4 °C for 5 min on a rocker and then
the extraction solution was collected. The metabolite extract was
cleared by centrifuging at 15,000×g for 10 min at 4 °C. Super-
natants were transferred to LC-MS silanised glass vials with PTFE
caps and either run immediately on the LC-MS or stored at −80 °C.
For analysis of nutrient uptake and efflux, the medium was
collected after 24 h and diluted 50-fold into extraction solution
(described above). Extracted medium was vortexed on a thermo-
mixer for 10 min at 4 °C before being frozen at −80 °C overnight.
The extracted medium was thawed on ice the next day and
following centrifugation, the cleared supernatants were trans-
ferred to silanised glass vials and either run immediately by LC-MS
or stored at −80 °C.
LC-MS analysis was performed on a Q Exactive Hybrid
Quadrupole-Orbitrap HF-X MS (Thermo Fisher Scientific) equipped
with a HESI II probe and coupled to a Vanquish Horizon UHPLC
system (Thermo Fisher Scientific). A total of 0.002ml of sample is
injected and separated by HILIC chromatography on a ZIC-pHILIC
2.1-mm. Samples are separated by ammonium carbonate, 0.1%
ammonium hydroxide, pH 9.2, and mobile phase B is acetonitrile.
The LC was run at a flow rate of 0.2 ml/min and the gradient used
was as follows: 0 min, 85% B; 2 min, 85% B; 17 min, 20% B;
17.1 min, 85% B; and 26min, 85% B. The column was maintained
at 45 °C and the mobile phase was also pre-heated at 45 °C before
flowing into the column. The relevant MS parameters were as
listed: sheath gas, 40; auxiliary gas, 10; sweep gas, 1; auxiliary gas
heater temperature, 350 °C; spray voltage, 3.5 kV for the positive
mode and 3.2 kV for the negative mode. Capillary temperature
was set at 325 °C, and funnel RF level at 40. Samples were
analysed in full MS scan with polarity switching at scan range
65–975m/z; 120,000 resolution; automated gain control (AGC)
target of 1E6; and maximum injection time (max IT) of 100 ms.
Identification and quantitation of metabolites was performed
using an annotated compound library and TraceFinder 4.1 soft-
ware. The “M+X” nomenclature refers to the isotopolog for that
given metabolite. Isotopologs are chemically identical metabolites
that differ only in their number of carbon-13 atoms. For instance,
“M+2 citrate” means that two of the six carbons in citrate are
carbon-13 while the other four are carbon-12. “M+4 citrate”
means that four of the six carbons in citrate are carbon-13 while
the other two are carbon-12.
Lipidomics
Cell pellets were washed twice with cold degassed PBS and
resuspended in methanol before transfer to silanised glass tubes.
Samples were spiked with 400 ng 12:0/12:0-PC, 100 ng 17:0-LPC,
300 ng 12:0/12:0-PE, and 100 ng 17:1-LPE; 0.88% NaCl; and
chloroform. The mixture was vortexed for 20 s at room
temperature and sonicated in an ice-cold water bath for 2 min.
Samples were centrifuged at 1100 rpm at 4 °C for 15 min. The
lower phase was collected. The upper phase was extracted with
synthetic lower phase (mix chloroform/methanol/0.88% NaCl at a
volume ratio of 2:1:1, after phase separation, take the lower phase
as synthetic lower phase for second extraction of lipid). The
resulting lower phase was combined and dried under vacuum at
room temperature with SpeedVac (Thermo Scientific) and re-
dissolved in chloroform. The final product was injected for LC-MS/
MS analysis using a Thermo Orbitrap Elite system (Thermo Fisher
Scientific) hyphenated with a five-channel online degasser, four-
pump, column oven, and autosampler with cooler Prominence
HPLC system (Shimadzu) for lipids analysis. In detail, lipid classes
were separated on a normal-phase silica gel column (2.1 ×
150mm, 4micro, MicoSolv Technology) with hexane/dichloro-
methane/chloroform/methanol/acetonitrile/water/ethylamine sol-
vent gradient based on the polarity of head group. High resolution
(240k atm/z 400)/accurate mass (with mass accuracy < 5 ppm) and
tandem MS (collision-induced fragmentation) were used for
molecular species identification and quantification. The identity
of lipid was further confirmed by reference to appropriate lipids
standards.
Oxygen consumption rate and extracellular acidification rate
measurements
Cells were seeded for 24 h prior to the assay and were 90–100%
confluent. For FAO measurements, cells were washed twice in KHB
buffer (111 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.25 mM CaCl2,
1.2 mM Na2HPO4, 100 μM L-carnitine, 5 mM HEPES and pH
adjusted to 7.4 with NaOH) before the addition of 100 μM BSA-
conjugated palmitate. Cells were incubated for 1 h to adjust to the
buffer before analysis using a Seahorse Bioanalyzer XF24 (Agilent).
Antimycin A and rotenone were added to establish the back-
ground oxygen consumption rate (OCR) and subtracted from the
basal OCR that is reported. For platelet-derived growth factor
receptor beta (PDGFRB) and epidermal growth factor receptor
(EGFR) studies on FAO, cells were pre-treated for 1 h with 25 ng/ml
PDGF-BB or EGF before addition of 100 μM α-cyclodextrin
conjugated palmitate. STO-609 was added at 10 μM and etomoxir
at 40 μM.
For extracellular acidification rate (ECAR) measurements, TERT
and MYC HME cells were seeded in HME serum-free medium in a
96-well Seahorse Bioanalyzer plate 24 h prior to analysis. Cells
were washed once with PBS before addition of Seahorse medium
supplemented with 5.50 mM glucose, 0.65 mM glutamine, and
0.10mM pyruvate. ECAR was measured using a XFe96 Seahorse
Bioanalyzer. Data were analysed using the Seahorse Wave
2.6 software.
Lipoprotein lipase activity assay
Lipoprotein lipase (LPL) activity assay was performed according to
manufacturer’s protocol (Sigma). Briefly, a master reaction mix was
prepared that contained assay buffer and an LPL substrate
emulsion and 195 μl was pipetted into a 96-well black clear
bottom (flat) plate. A total of 5 μl of HME cell lysate was added
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using a multichannel pipette and the plate was immediately
placed on a fluorimeter and read (Ex= 365; Em= 485) every 80 s
for 1 h at 37 °C. Cell lysate-free wells were used for background
subtraction. A Lowry assay was used to assess protein concentra-
tion in the cell lysates.
Carbon-14 FAO assay
HME cells were seeded for 24 h prior to the FAO assay. The cells
were washed in PBS and fresh medium supplemented with
200 μM carnitine and 1.2 μCi (20 μM) U-14C-palmitate conjugated
with α-cyclodextrin and incubated for 4 h at 37 °C. Whatman paper
soaked in 5 N NaOH was attached to the lid of each dish and 2.6 N
HClO3 was added to the medium to evolve and capture the
14CO2
over 1 h. Whatman paper was counted directly in scintillation fluid.
For acid soluble metabolites (ASMs), the medium was removed
and 4 N KOH was added to hydrolyse acyl-CoA esters (saponify) at
60 °C for 30 min; 1 M NaC2H3O2 and 3 N H2SO4 were added and
samples were vortexed and transferred to a glass vial. A 2:1
mixture of CHCl3:CH3OH was added and samples were vortexed
and then 4mM MgCl2 was added and samples were vortexed
again before a short spin to separate the phases. The upper
(aqueous) phase was added to scintillation fluid and using a
scintillation counter. Lowry assay was used to assay protein
content and normalise the data.
RNA-sequencing and ingenuity pathway analysis
RNA was isolated using a Qiagen RNeasy kit. Ribodepletion was
performed using an Epicentre Ribo Zero kit. Libraries were
prepared according to the Illumina TruSeq protocol and
sequenced on an Illumina GAIIx. Tophat 1.4.1 align versus hg18
using ensembl (ncbi36.54 transcriptome). Cuffdiff 2.0.2 was used
to do pairwise comparisons with fragment bias and multi-read
corrections. Pairwise sample comparisons were performed using
Cuffdiff and False Discovery Rate (FDR) estimated by
Benjamini–Hochberg method was used to create a set of
significant genes that pass FDR <5% cut-off. All the genes that
met the FDR 5% cut-off also had at least 4.8-fold change
difference in all comparisons. Samples were normalised using
upper quartile normalisation and considered significant at FDR <
5%. Gene networks, canonical pathways, and functional analyses
were generated through the use of ingenuity pathway analysis
(IPA) (https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis).22 There was only one replicate per condition,
however, since Cuffdiff uses beta negative binomial distribution as
an underlying statistical model, the significance takes into account
the read count nature of RNA sequencing data and gives an extra
level of confidence compared to using only fold change.
Data mining and human patient data
All patient tumour mRNA expression data, z-scores, copy number
gains, and gene amplification data were obtained from www.
cbioportal.org.23,24 Breast cancer patient tumours were classified
based on the molecular subtypes as called by the METABRIC database
and PAM50+claudin-low.1 All METABRIC expression data and patient
metadata are freely available through www.cbioportal.org.
Calcium imaging
Cells were loaded (20min, 37 °C) with fluo4 AM (10 µM; Life
Technologies, Paisley, UK) and membrane permeant caged IP3
(10 µM; SiChem) in a solution containing (mM) sodium glutamate,
80; NaCl, 54; KCl, 5; MgCl2, 1; CaCl2, 0.1, Hepes, 10; glucose, 10; and
0.2, EDTA (to remove heavy metals); the pH adjusted at room
temperature to 7.3 using NaOH.
After loading, cells were washed and imaged in medium (HME
cells Basal Serum-Free Medium supplemented with the HMEC
Supplement Kit and 1× penicillin–streptomycin).
Two-dimensional [Ca2+]c images were obtained using a wide-
field digital imaging system. Excitation illumination was provided
by a monochomator (PTI Inc., West Sussex, UK) to give 490 nm
(bandpass 5 nm), coupled via a liquid light guide to a Nikon
TE2000U microscope (Nikon UK, Surrey England). Fluorescence
emission was collected by the objective lens (×40, NA 1.3) and
transmitted to a cooled, back-illuminated, frame transfer CCD
camera with on-chip electron multiplication (Cascade 512B;
Photometrics Tuscan, AZ, USA) controlled by Winfluor (University
of Strathclyde, Glasgow, UK). Images were collected at a frequency
of 10 Hz unless otherwise indicated. Photolysis of caged-IP3 was
achieved using a frequency-tripled ND:Yag (wavelength 355 nm)
laser attached directly to the microscope (Rapp Optoelektronic,
Hamburg, Germany). The position of the photolysis site (~2 µm
diameter) was computer controlled (Rapp Optoelektronic). The
duration of the photolysis pulse was 1 ms and energy, measured
at the objective, 100 µW.
[Ca2+] images were analysed using the program Metamorph 7.5
(Molecular Devices Ltd., Wokingham, U.K.) or Image Pro 7.0 (Media
Cybernetics, MD). To compensate for variations in fluorescence
across the imaging field, e.g., from irregularities in focus of the
cells, fluorescence signals were background subtracted and
expressed as ratios (F/F0) of fluorescence counts (F) relative to
baseline (control) values (taken as 1) before stimulation (F0).
PDGF-BB was diluted in 1% BSA–PBS and an aliquot injected
(1:100 dilution) into the imaging bath to give 100 ng/ml.
Responders were classified as those cells with a peak F/F0 of
>1.15 that occurred shortly after PDGF exposure (within 30 s).
RESULTS
Generation of HME cells expressing TERT, MYC, or HER2
HME cells have been routinely used as a model system to study
the oncogenic transformation of non-immortalised breast epithe-
lial cells to immortalised transformed cancer cells.25–27 Further-
more, HME cells lack expression of the oestrogen receptor (ER)
and therefore provides the opportunity to model the develop-
ment of ER-negative breast cancers.28 A more recent study
showed that the phenotype and cellular behaviour that emerged
in a separate model of MYC expressing HME cells was very similar
to that of MDA-MB-231 cells, a TNBC cell line.29 To identify novel
targets associated with the activation of FAO by MYC, we used
post-selection HME cells that stably express wild-type MYC (MYC
HME cells) or a mutant version of MYCT58A (T58A HME cells) that
has a slightly longer half-life (Fig. 1a).30,31 MYC is able to
immortalise HME cells in part through the stabilisation of TERT.25
To ensure that the effects we were observing in the two MYC HME
cells lines were specific to MYC expression and not due to TERT,
we also used an isogenic HME cell line that instead had been
immortalised by direct stable expression of TERT (TERT HME cells;
Fig. 1a).31,32 Lastly, we introduced human epidermal growth factor
receptor 2 (HER2) into TERT HME cells to produce HER2-
overexpressing HME cells (HER2 HME cells). HER2 is an oncogene
that is commonly amplified in ~20% of breast cancers, is mutually
exclusive with TNBC, and serves as a separate model of oncogene
overexpression that is relevant to breast cancer (Fig. 1a). All four
pools of isogenic HME cells cell lines (TERT, MYC, T58A, and HER2)
are negative for ER and progesterone receptor (PR) (Fig. 1b). We
therefore used MYC HME cells and T58A HME cells as representa-
tive models of TNBC in which we could cleanly delineate the
effects of MYC on FAO.
MYC is sufficient to stimulate FAO in HME cells
We initially wanted to test if MYC is sufficient to induce FAO in
HME cells. To measure FAO, we incubated HME cells in uniformly
labelled carbon-14 palmitate (14C16-palmitate). We then measured
14CO2 production by the HME cells as well as intracellular levels of
14C-labelled ASMs (Fig. 1c). ASMs are defined as carbon-14-
labelled intracellular polar metabolites that are formed from the
catabolism of 14C16-palmitate, such as acetyl-CoA and tricarboxylic
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acid (TCA) cycle intermediates. Importantly, all FAO activity was
blocked by the addition of etomoxir, an inhibitor of the rate
limiting enzyme of FAO, carnitine palmitoyltransferase 1A (CPT1A)
(Fig. 1c). This FAO assay showed that MYC and T58A HME cells
have significantly higher rates of FAO compared to TERT and HER2
HME cells. These results were also confirmed by measuring OCRs
on a Seahorse Bioanalyzer when palmitate conjugates were
provided as a sole fuel substrate (Supplementary Fig. S1a).
Although FAO assays showed that MYC and T58A HME cells
have a higher capacity to oxidise fatty acids, it did not inform
about the contribution of fatty acids to mitochondrial metabolism
compared to other fuel sources such as glucose or glutamine. To
address this, we incubated cells for a short period (30 min) in
uniformly labelled carbon-13 (13C) glucose, glutamine, and
palmitate to compare the oxidation of these three nutrient
sources using citrate labelling as a readout. While we did detect
13C-labelling of citrate by 13C-palmitate in MYC HME cells, we
barely detected labelling of citrate by 13C-palmitate in TERT HME
cells, which agrees with the results in Fig. 1c and Supplementary
Fig. S1a, and further suggests that TERT HME cells engage very low
levels of FAO (Fig. 1d and Supplementary Fig. S1b). Although
statistically significant, we detected only subtle differences in
TERT
HER2
100
75
50
10
8
6
4
2
100
75
50
20
15
10
5
0
0
100
75
50
15
10
5
0
MYC
Tubulin
TE
RT
MY
C
T5
8A
HE
R2
TE
RTMY
C
TE
RT
MY
C
T5
8A
HE
R2
T4
7D
MD
AM
B4
68
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
TE
RTMY
C
ER
500 12
9
6
3
0
400
300
200
100
0
PR
Actin
M + 0
M + 1
M + 2
M + 3
M + 4
M + 5
M + 6
M + 0
M + 1
M + 2
M + 3
M + 4
M + 5
M + 6
M + 0
M + 1
M + 2
M + 3
M + 4
M + 5
M + 6
a b c
CP
M
 (A
SM
)/μ
g/
4 
h
CP
M
 (C
O 2
)/μ
g/
4 
h
AS
M
CO
2
CO
2
CO
2
CO
2
Et
o
AS
M Et
o
AS
M Et
o
AS
M Et
o
****
****
****
***
d
%
 la
be
llin
g 
of
 c
itr
at
e
(F
rom
 13
C-
pa
lm
ita
te
)
%
 la
be
llin
g 
of
 c
itr
at
e
(F
rom
 13
C-
gl
ut
am
in
e)
%
 la
be
llin
g 
of
 c
itr
at
e
(F
rom
 13
C-
gl
uc
os
e)
N.S.
N.S.
N.S.N.D.
N.S.
N.S.
N.D.N.D. N.D. N.D.
N.D.
e
f
**
**
******
****
****
N.S.
N.S.
****
****
**
Fig. 1 MYC expression is sufficient to induce fatty acid oxidation in human mammary epithelial cells. a Immunoblot analysis of TERT,
HER2, and MYC protein expression in HME cell lines (stable pools). b Immunoblot analysis of oestrogen receptor (ER) and progesterone
receptor (PR) in HME cells and human breast cancer cell lines. T47D breast cancer cells are positive for both ER and PR and served as a control
for hormone receptor-positive cells. MDA-MB-468 lack expression of ER, PR, and HER2 and served as a control for triple negative breast cancer
cells. c FAO of U-14C-palmitate in HME cells. Left y-axis represents carbon-14 labelling of acid soluble metabolites (ASM; solid bars). Right y-axis
represents the capture of 14CO2 (black slashed bars) from HME cells, a readout of FAO. Etomoxir treatment is represented by the right y-axis
and shows the inhibition of 14CO2 production from U-
14C-palmitate (checkered bars). Throughout the manuscript, TERT= grey, MYC= red,
T58A= green, HER2= blue; n ≥ 3 independent experiments. Error bars represent mean ± standard deviation (s.d.). p Values were calculated
using an unpaired Student’s t-test and are relative to TERT HME cells for each respective measurement. d–f LC-MS-based quantification of
citrate labelling from cells treated with 0.05 mM U-13C-palmitate (d), 5.5 mM U-13C-glucose (e), and 0.65mM U-13C-glutamine (f) for 30min.
The carbon-13 labelling is presented as a percent abundance of each isotopolog relative to the total citrate pool; n= 3 independent samples.
Samples were measured in a single run on the mass spectrometer. Adjusted p values were calculated using an ordinary two-way ANOVA and
Sidak’s multiple comparison test for each isotopolog; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N.S.= not significant, N.D.= not
detected.
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citrate labelling from 13C-glucose (Fig. 1e and Supplementary
Fig. S1c). 13C-palmitate was oxidised at ~25% the rate of 13C-
glucose; however, this is likely an underestimation of actual level
of FAO in MYC HME cells, since there are other fatty acids present
in the culture medium which were also likely oxidised along with
the 50 μM 13C-palmitate that was provided. We repeated our
metabolic flux analysis by measuring citrate labelling for longer
periods (4 and 8 h) after 13C-palmitate addition in TERT, MYC, and
HER2 HME cells. By 8 h, >22% of the citrate pool was labelled by
13C-palmitate in MYC HME cells, while <6% was labelled in either
TERT or HER2 HME cells (Supplementary Fig. S1d). Similar labelling
patterns were measured for other TCA cycle intermediates,
including α-ketoglutarate and malate (Supplementary Fig. S1e, f).
These results suggest that MYC expression was sufficient to induce
FAO in human breast cells.
One of the more striking findings from the 13C tracer studies
was that MYC HME cells displayed significantly higher labelling of
citrate by 13C-labelled glutamine, suggesting high flux of
glutamine carbon into the TCA cycle (Fig. 1f and Supplementary
Fig. S1g). It has been well documented that MYC induces
upregulation of glutaminase expression33 and we find that
mitochondrial-localised glutaminase 2 (GLS2) expression was
upregulated in MYC and T58A HME cells in a MYC-dependent
manner (Supplementary Fig. S1h). Interestingly, glutamine uptake
was not different between TERT and MYC HME cells; however,
glutamate efflux was substantially lower in MYC HME cells
(Supplementary Fig. S1i, j). Lower glutamate efflux would be
compatible with our observations of higher GLS2 expression and
higher flux of glutamine carbon into the TCA cycle. Altogether,
these findings could suggest that TERT HME cells are more
dependent on an alternative metabolic pathway for ATP produc-
tion and indeed we find that TERT HME cells consume slightly
more glucose and secrete higher amounts of lactate suggesting
that pyruvate may be diverted to lactate instead of to the
mitochondria in TERT HME cells (Supplementary Fig. S1k, l). We
also used a Seahorse bioanalyzer to measure the ECAR as an
alternative method to investigate lactate efflux from TERT and
MYC HME cells (Supplementary Fig. S1m). This separate approach
showed that TERT HME cells had a slightly higher ECAR compared
to MYC HME cells. Importantly, the higher flux of palmitate and
glutamine into the TCA cycle of MYC HME cells does not appear to
be due to the presence of more mitochondria in MYC HME cells
since there are no differences in Mitotracker Green labelling or
mitochondrial DNA content between the four HME cell lines
(Supplementary Fig. S1n–p).
MYC HME cells are enriched with fatty acid metabolism genes and
have phospholipid profiles indicative of fatty acid uptake
Having established a TNBC model system of isogenic HME cells
lines and shown that MYC expression is sufficient to induce FAO in
HME cells, we next wanted to identify novel targets that might
contribute to the activation of FAO in MYC HME cells. Since MYC is
a transcription factor, we performed NextGen RNA sequencing on
TERT, MYC, and HER2 HME cells to gain further insight into
potential mechanisms of how MYC affects FAO in HME cells
(Supplementary Tables S1 and S2). Differentially expressed genes
were mapped to networks available in the Ingenuity database.
Five networks were identified and ranked by a network score
produced by the IPA, that ranged from 30 to 45 (Supplementary
Table S3). The score takes into account the number of
differentially expressed genes (FDR < 5%) and the size of the
network to approximate the relevance of the network to the
original list of genes. The only network in MYC HME cells
associated with metabolism was “lipid metabolism” (IPA Network
4), whose components are shown in Fig. 2a. The IPA also indicated
that some of the most significantly altered canonical signalling
pathways (377 genes; FDR < 5%; Min. fold: 6.81) in MYC HME cells
were involved in lipid metabolism, including atherosclerosis
signalling, LXR/RXR activation, and PPAR signalling (Fig. 2b, black
boxes). Gene expression analysis of an unbiased list of 163
different genes (Supplementary Table S4) associated with lipid
metabolism across TERT, MYC, and HER2 HME cells revealed a
significant enrichment of upregulation in MYC versus TERT (1.4-
fold over all upregulated genes, p= 5 × 10−8 by Fisher Exact Test).
Notable functions for those genes were related to lipid transport,
acyl-CoA metabolism, mitochondrial β-oxidation, and lipases. Our
findings agree with Camarda et al. who also reported a strong
representation of fatty acid metabolism genes in TNBC patients.10
We next performed a lipidomic analysis that revealed that
phosphatidylcholine (PC) and cardiolipin contained longer, more
unsaturated fatty acyl chains compared to TERT cells (Supple-
mentary Fig. S2a, b), a pattern commonly observed in cells that are
more dependent on fatty acid uptake than de novo fatty acid
synthesis.19,34 These results also agree with the predicted
activation of “atherosclerosis signalling” (Fig. 2b), a process closely
associated with enhanced lipid uptake. Furthermore, MYC HME
cells contained higher amounts of lipid breakdown products, such
as monoacylglycerols (MAGs) and free fatty acids (FFAs), but had
25% less triacylglycerol (TAG), which is the main lipid storage
molecule of a cell (Supplementary Fig. S2c). Overall our
transcriptomic, bioinformatic, and lipidomic results suggested
that MYC HME cells are not simply scavenging fatty acids to store
as TAG, but rather actively metabolising them.
MYC promotes fatty acid uptake and lipase activity in HME cells
We were interested in identifying potential new targets that may
be involved in FAO in TNBC. We therefore investigated which
specific genes displayed the largest upregulation and were
associated with IPA Network 4 and the canonical signalling
pathway of atherosclerosis signalling. Fatty acid transporter CD36
(>800-fold upregulation) and LPL (>80-fold upregulation) were
two of the most highly upregulated fatty acid metabolism genes
in MYC HME cells (Fig. 2a, b and Supplementary Table S1). We
confirmed upregulation of CD36 and LPL by qRT-PCR in MYC and
T58A HME cell lines (Fig. 2d, e). The physiological function of LPL is
to catalyse the release of fatty acids from TAGs that are present in
the bloodstream. The liberated fatty acids can then be scavenged
by fatty acid transporters, such as CD36. Together, the marked
upregulation of LPL and CD36 in MYC HME cells suggested that
they may be involved in the mobilisation and consumption of
fatty acids in MYC HME cells. MYC HME cells had significantly
higher lipase activity compared to TERT or HER2 HME cells (Fig. 2f).
We confirmed surface expression of the fatty acid transporter
CD36 in MYC HME cells by flow cytometry (Fig. 2g). We then
measured fatty acid uptake using time-lapse fluorescent micro-
scopy on TERT and MYC HME cells incubated with BODIPY-labelled
dodecanoic acid (BODIPY-C12). MYC HME cells showed higher
BODIPY-C12 uptake compared to TERT HME cells (Supplementary
Movies S1 and S2).
Fatty acid uptake through CD36 supports FAO in MYC HME cells
We predicted that CD36-mediated fatty acid uptake may be
involved in the ability of MYC HME cells to oxidise fatty acids. We
generated stable pools of MYC HME cells that express two
different TetON-inducible shRNAs against CD36 (Fig. 2h). shRNA-
mediated silencing of CD36 expression inhibits FAO in MYC HME
cells, suggesting that CD36 is a major contributor to the import of
fatty acids that are destined for oxidation in the mitochondria
(Fig. 2i).
Multiple studies have suggested that mitochondria-localised
carnitine acyltransferases, such as CPT1A and CPT2, are important
regulators of FAO in breast cancer and critical for breast cancer
growth.10,35,36 MYC and T58A HME cells had ~2-fold increases in
CPT mRNA expression compared to TERT and HER2 (Supplemen-
tary Fig. S2d, e). LC-MS-based metabolomics analysis showed that
MYC and T58A HME cells also have significantly higher uptake of
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carnitine, which is a substrate of CPT1A and a necessary amino
acid for long-chain fatty acid import into mitochondria (Supple-
mentary Fig. S2f). We next measured the levels of and labelling of
acetyl-carnitine, a metabolite closely linked to FAO and whose
increased presence suggests active FAO.37,38 Acetyl-carnitine is
synthesised from acetyl-CoA in the mitochondria by the enzyme
carnitine acetyltransferase. Since acetyl-carnitine is an “end
product” that cannot be further metabolised, it can only be
converted back into acetyl-CoA. It is therefore important to take
into account the total level of acetyl-carnitine in the cell when
measuring acetyl-carnitine synthesis. Although there were differ-
ences between TERT and MYC HME cells with respect to which
fuel was used for acetyl-carnitine synthesis, when we added
together the percent labelling of acetyl-carnitine by 13C-glucose,
13C-palmitate, and 13C-gutamine, there were no differences
between MYC HME cells (16.46%) and TERT HME cells (16.74%)
(Supplementary Fig. S2g–i). However, we did find that the total
mitochondrial acetyl-carnitine level was >4 times higher in MYC
HME cells compared to TERT HME cells (Supplementary Fig. S2j–l),
suggesting a much higher rate of acetyl-carnitine production in
MYC HME cells. In addition, we detected efflux of acetyl-carnitine
into the medium from MYC and T58A HME cells, but not TERT and
HER2 HME cells, further evidence of highly active FAO in MYC HME
cells (Supplementary Fig. S2m). Overall, these results suggest that
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MYC causes increased fatty acid uptake, increased carnitine
uptake, and increased FAO in HME cells and identified CD36 as
a potential mediator of fatty acid uptake and oxidation in MYC
HME cells.
CAMKK2 phosphorylates AMPK in MYC HME cells
The increase in the expression of fatty acid import machinery at
both the plasma membrane by CD36 and inner mitochondrial
membrane by CPT1A and CPT2 facilitates increased uptake and
FAO in MYC HME cells. However, one of the main mechanisms by
which FAO is regulated is through 5′-AMP-activated protein kinase
(AMPK)-dependent phosphorylation of acetyl-CoA carboxylase
(ACC). ACC produces malonyl-CoA, a potent inhibitor of CPT1A.
Inhibition of ACC by AMPK phosphorylation therefore alleviates
CTP1A inhibition to stimulate FAO. Camarda et al. showed that
TNBC, compared to receptor-positive breast cancer, has lower
expression of fatty acid synthase (FASN) and ACC and that this
lower expression was associated with worse prognosis.10 Although
we did not observe downregulation of FASN or ACC in MYC HME
cells, we did find that MYC expression caused increased AMPK
phosphorylation in HME cells (Fig. 3a and Supplementary Fig. S3a).
AMPK is typically phosphorylated in response to nutrient stress,
such as an increase in the AMP:ATP ratio. However, metabolomic
analysis indicated that the AMP, ADP, and ATP concentrations are
not different between TERT and MYC HME cells, ruling out a role
for ATP stress in AMPK phosphorylation (Supplementary Fig. S3b).
There is a second known AMPK kinase called calcium (Ca2+)/
calmodulin activated kinase kinase 2 (CAMKK2) that can
phosphorylate AMPK in a Ca2+/calmodulin (CaM)-dependent
manner.39 We observed a ~2-fold increase in CAMKK2 mRNA
and protein expression in MYC and T58A HME cells (Supplemen-
tary Fig. S3c, d). Inhibition of CAMKK2 by a pharmacological
inhibitor (STO-609) or siRNA-mediated silencing of
CAMKK2 strongly inhibited AMPK phosphorylation in MYC and
T58A HME cells (Fig. 3a and Supplementary Fig. S3e). Conversely,
activation of CAMKK2 using a Ca2+ ionophore (A23187) causes a
robust increase in the phosphorylation of AMPK (Fig. 3a).
Altogether these findings suggest that activation of AMPK occurs
independently of energy stress and is regulated by CAMKK2 in
MYC HME cells. Importantly, STO-609 caused a time-dependent
decrease in FAO in MYC HME cells, thereby suggesting that
CAMKK2 activity helps to promote FAO (Fig. 3b).
Ca2+ signalling via CAMKK2 helps to promote FAO
When Ca2+ binds to CaM, it increases the affinity of CaM for
CAMKK2. Binding of the Ca2+ bound CaM to CAMKK2 induces
autophosphorylation and full activation of CAMKK2. We therefore
explored the importance of Ca2+ in CAMKK2 activation and found
that chelation of intracellular Ca2+ by BAPTA-AM causes a
decrease in the phosphorylation of AMPK, suggesting that Ca2+
signalling is involved in the CAMKK2-dependent phosphorylation
of AMPK (Supplementary Fig. S3f). This result also suggested that
MYC HME cells may have altered Ca2+ signalling. To further
investigate this, we compared Ca2+ signalling in TERT and MYC
HME cells by pre-loading them with the intracellular Ca2+
indicator Fluo-4 and caged IP3. Caged IP3 is inert until a pulse of
ultraviolet (UV) light is given to release the IP3, which then allows
comparison of IP3-induced Ca
2+ release in TERT and MYC HME
cells. The Ca2+ release in response to IP3 uncaging in MYC HME
cells was extremely fast and often occurred so quickly that it was
buried within the flash artefact of the UV pulse (Supplementary
Fig. S3g). We then quantified the time from uncaging to the half
maximal peak of Ca2+ release and found that MYC HME cells
rapidly respond to IP3 as opposed to TERT cells, which exhibited a
significant delay (Supplementary Fig. S3g, h).
The caged-IP3 experiments suggested changes to intracellular
Ca2+ handling in MYC HME cells, we therefore mined the RNA
sequencing data to identify potential modulators of Ca2+
signalling. We found that MYC and T58A HME cells have much
lower expression of three major Ca2+ transporters: the Na+/Ca2+
exchanger SLC8A1, a golgi-resident Ca2+ pump ATP2C2, and a
plasma membrane Ca2+ ATPase ATP2B4 (Supplementary Fig. S3i–k,
Supplementary Table S1). Interestingly, depletion of MYC by siRNA
resulted in increased expression of Ca2+ transporters suggesting
that MYC may modulate Ca2+ handling as part of a mechanism by
which it regulates cell metabolism (Supplementary Fig. S3l, m).
We also identified significant upregulation of PDGFRB in MYC
HME cells (Fig. 3c and Supplementary Fig. S3n). PDGFRB is a
receptor tyrosine kinase (RTK) that induces intracellular Ca2+
release and has strong links to epithelial-to-mesenchymal transition
(EMT), cell migration, and cancer progression.40,41 To assess the role
of PDGFRB in the activation of FAO, we loaded MYC and TERT HME
cells with the Ca2+-binding dye Fluo-3 and measured intracellular
Ca2+ release in response to “puffing” its ligand, PDGF-BB, onto the
cells (as previously described in ref. 42). In the MYC HME cells that
responded (3/18), there is a strong rise in cytosolic Ca2+
concentration ([Ca2+]c) with a mean fold change of 2.16 ± 0.12
(Fig. 3d). We also noted that one of the initial responders displayed
a second [Ca2+]c peak, suggesting an oscillation in Ca
2+ release
(Fig. 3d). TERT HME cells that responded (5/29) showed a later (from
60 s onwards), modest rise in [Ca2+]c (1.32 ± 0.11) (Fig. 3d). Overall,
TERT HME cells have a delayed, weak response to PDGF-BB while
MYC HME cells had Ca2+ rises that were faster, higher, and
sustained for longer in response to PDGF-BB stimulation.
Fig. 2 MYC HME cells use LPL and CD36 to mobilise and take up fatty acids. a Interaction map of the lipid metabolism gene network in
MYC HME cells. Ingenuity Pathway Analysis was used to create the interaction map. Black circles highlight lipid metabolism genes CD36 and
LPL. b Top canonical signalling pathways in MYC versus TERT HME cells based on RNA sequencing data (377 genes; FDR < 5%; minimum fold
change: 6.81). Ingenuity Pathway Analysis was used to identify the pathways. Black boxes highlight gene ontologies associated with lipid
metabolism. The value next to each bar represents the number of altered genes within the indicated signalling pathway. The colour of the bar
indicates the percent of genes within the pathway that are differentially regulated. The black dotted line marks significance (FDR < 5%). c Heat
map showing the relative expression of 163 genes associated with lipid metabolism in TERT, MYC, and HER2 HME cells (1.4 over all
upregulated genes in MYC HME cells; p= 5 × 10−8 by Fisher Exact Test). Notable functions for those genes were related to lipid transport, acyl-
CoA metabolism, mitochondrial b-oxidation, and lipases. d, e qRT-PCR analysis of mRNA expression of CD36 and LPL in HME cell lines; n= 3
independent experiments. All values are relative to β-actin and normalised to TERT HME cells. Bars represent mean with upper and lower
limits; p values were calculated using an unpaired Student’s t-test. f Measurement of LPL activity in HME cell lysates; n= 4 independent
experiments. Error bars represents mean ± s.d; p values were calculated using an unpaired Student’s t-test. g Flow cytometric analysis of
CD36 surface expression in TERT (grey) and MYC (red) HME cells. Representative histograms from n= 2 independent experiments. αGFP (IgG)
was used an isotype control (top histogram). h Relative mRNA expression of CD36 in MYC HME cells+ pTRIPZ, MYC HME cells+ shCD36#2,
and MYC HME cells+ shCD36#3. Cells were treated with 0.5 μg/ml doxycycline for 48 h to induce shRNA expression; n= 3 independent
experiments. Error bars represent mean with upper and lower limits; p values were calculated using an unpaired Student’s t-test. i Basal OCR of
MYC HME cells+ pTRIPZ, MYC HME cells+ shCD36#2, and MYC HME cells+ shCD36#3. Cells were treated with doxycycline to induce shRNA
expression prior to measurement of the OCR in the presence of 0.10 mM palmitate; n= 5 independent experiments. Error bars represent
mean ± standard error of the means (s.e.m.); p values were calculated using an ordinary one-way ANOVA with Tukey’s multiple comparisons
test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N.S.= not significant.
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We next tested if PDGFRB stimulation was able to promote FAO
in MYC HME cells. A 1-h preincubation of MYC HME cells in the
presence or absence of PDGF-BB demonstrated that PDGFRB
signalling causes a large increase in FAO (Fig. 3e). PDGF-BB-
induced FAO could be inhibited by STO-609 or etomoxir (Fig. 3f).
STO-609 treatment in the absence of growth factor did not have a
substantial effect on FAO after 1-h preincubation (Fig. 3b),
suggesting the effects were specific to the PDGFRB response.
Etomoxir treatment in the absence of growth factors suppressed
FAO (Supplementary Fig. S3o); however, this was expected since
the cells likely engage in some degree of FAO in the absence of
stimulation. Interestingly, these results were also seen when we
stimulated a different RTK, EGFR, with EGF (Supplementary
Fig. S3p, q). Altogether, these results suggest that RTK-mediated
Ca2+ release and subsequent stimulation of CAMKK2 is one way
by which MYC expressing HME cells may promote FAO.
CAMKK2 inhibition has cytostatic and cytotoxic effects on MYC
HME cells
We next wanted to determine the long-term effects of inhibiting
CAMKK2 signalling on proliferation and survival of MYC HME cells.
STO-609 caused cytostatic effects in MYC and T58A HME cells as
evidenced by decreases in the percentage of cells in S and G2/M
phases of the cell cycle (Fig. 4a–d and Supplementary Fig. S4a).
STO-609 also caused cell death in 15–20% of MYC HME cells
(Fig. 4a–d and Supplementary Fig. S4a). Etomoxir, a potent FAO
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inhibitor, caused substantial cell death in MYC and T58A HME cells.
In contrast, TERT and HER2 HME cells had little to no cell death in
response to STO-609; however, there were decreases in S phase
and large increases in G2/M phase of the cell cycle. Other than a
decrease in the percentage of S phase cells, TERT and HER2 HME
cells were largely unaffected by treatment with etomoxir.
Inhibition of CAMKK2 or CD36 strongly reduces MYC HME cell
migration
From the previous time-lapse movies of BODIPY-C12 uptake, we
noticed that MYC HME cells were highly migratory compared to
TERT HME cells (Supplementary Movies 1 and 2). In addition, IPA
predicted “cellular movement” as the top hit for molecular and
cellular functions (p= 1.62e−18; Fig. 4e). When we tracked the
migration of individual cells using time-lapse microscopy, we
measured a striking 10-fold increase in MYC HME cell migration
speeds compared to TERT or HER2 cells (Fig. 4f). Depletion of CD36
or inhibition of CAMKK2 significantly impaired MYC HME cell
migration (Fig. 4f and Supplementary Fig. S4b). These results
suggest that CAMKK2 and CD36 are important contributors to cell
migration.
The fatty acid metabolism gene signature of MYC HME cells is
highly representative of claudin-low TNBC
We had thus far found that expression of oncogenic levels of MYC
in human breast cells induces a multigenic program characterised
by changes in RTK signalling, intracellular Ca2+ handling,
CAMKK2 signalling, fatty acid uptake, and FAO (Supplementary
Fig. S4c). We next sought to determine if the fatty acid metabolism
gene signature of the MYC HME cells is representative of specific
molecular subtype of breast cancer. Since MYC and T58A HME
cells lack ER, PR, and HER2 expression (Fig. 1a, b), we predicted
that their gene expression patterns would most closely reflect
TNBC. Bioinformatic analysis of the METABRIC breast cancer
database of ~2000 patient tumour samples showed that MYC is
indeed most highly expressed in claudin-low (CL) and basal breast
cancers, which are also the two subtypes most highly enriched for
TNBCs (Fig. 5a).1,2,23,24 However, CL breast cancers specifically had
the highest expression of CD36, LPL, and PDGFRB (Fig. 5b–d). We
next compared the expression of MYC, CD36, LPL, and PDGFRB in
basal-TNBC versus CL-TNBC. Although we did not observe a
significant difference in MYC (p= 0.08) or LPL (p= 0.11) expres-
sion between basal-TNBC and CL-TNBC, we did find that CL-TNBC
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tumours had significantly higher expression of CD36 (p < 0.0001)
and PDGFRB (p < 0.0001) (Supplementary Fig. S5a–d).
There was significant correlation in expression between CD36 and
LPL (Spearman 0.63; p= 3.29e−12) and CD36 and PDGFRB (Spear-
man 0.55; p= 3.42e−9), suggesting that high expression of these
genes often co-occurs in CL-TNBC (Fig. 5e, f). According to the
METABRIC database, the two genes with the highest degree of co-
expression with CD36 were pyruvate dehydrogenase kinase 4 (PDK4;
Spearman 0.84; p= 1.73e−17) and fatty acid binding protein 4
(FABP4; Spearman 0.77; p= 2.27e−21) (Fig. 5g, h). Similar to CD36,
PDK4 and FABP4 are also highly expressed in CL breast cancers
compared to all other molecular subtypes with the exception of
normal-like breast tumours. Furthermore, when we compared the
expression of PDK4 an FABP4 in basal-TNBC versus CL-TNBC, we
again found significantly higher expression of PDK4 (p < 0.0001) and
FABP4 (p < 0.0001) in CL-TNBC (Supplementary Fig. S5e–h).
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PDK4 is a negative regulator of glucose oxidation that
phosphorylates and thereby inhibits pyruvate dehydrogenase
activity. There is extensive literature on the role of PDK4 in
stimulating mitochondrial FAO.43,44 PDK4 is often thought of as a
molecular switch between glucose oxidation and FAO, such that
high PDK4 activity promotes FAO.43 Interestingly, it has been
shown that fatty acid influx and enforced expression of CD36 are
able to induce the expression of PDK4 in muscle suggesting a
strong metabolic link between the two.45 Knockdown of PDK4
impacts breast cancer metabolism and high PDK4 expression has
been shown to predict poorer survival in breast cancer patients.46
FABP4 has been shown to promote the direct transfer of lipids
from adipocytes to ovarian cancer cells that then promotes in vitro
and in vivo tumour growth.47 A more recent study showed that
exogenous expression of FABP4 in CL-TNBC cells (MDA-MB-231)
increased proliferation.48 Interestingly, FABP4 is on the same arm
of chromosome 8 as MYC and is often co-amplified with MYC in
breast cancer (Supplementary Fig. S5i, j). Since we used
exogenous expression of MYC to increase MYC expression in
HME cells, this may explain why FABP4 was not upregulated in
MYC HME cells (Supplementary Table S1).
We created a “fatty acid metabolism gene signature” consisting
of CD36, LPL, PDK4, and FABP4 and checked each molecular
subtype of breast cancer for upregulation or amplification of these
genes. If any one or combination of these genes was upregulated
or amplified in the tumour, the patient was classified as “high fatty
acid metabolism”. All patient tumours that lacked upregulation or
amplification of all four of these genes were classified as “low fatty
acid metabolism”. We next tested if this four gene fatty acid
metabolism gene signature predicts poorer survival only in TNBC
or in all breast cancer subtypes. Despite consistent correlation in
expression between CD36, LPL, PDK4, and FABP4 in all breast
cancer subtypes (data not shown), the only subtype that displayed
poorer survival was CL-TNBC (p= 0.0119; HR= 1.92; Fig. 5i, j and
Supplementary Fig. S5k–p). We performed a Cox regression
analysis using the fatty acid metabolism gene signature and age
and found that both are independent predictors of survival (data
not shown). Our bioinformatic analyses suggested that this set of
fatty acid metabolism genes and, by extension, FAO may be
associated with more aggressive disease in CL-TNBC, but not
necessarily other subtypes of TNBC (Fig. 5g, h and Supplementary
Fig. S6h–m).
We next compared the expression of SLC8A1, ATP2C2, and
ATP2B4 with respect to MYC gene amplification in CL-TNBC.
Although it did not reach significance, SLC8A1 and ATP2B4 did
have lower expression levels in CL-TNBC tumours that have MYC
gene amplification (p= 0.07 and p= 0.09, respectively) (Fig. 5k, l).
No differences in expression were noted for ATP2C2 with regard
to MYC gene amplification in CL-TNBC (Fig. 5m). We then tested if
CD36Hi tumours had lower expression of Ca2+ transporters. We did
not detect any differences in Ca2+ transporter expression in
CD36Hi versus CD36Lo CL-TNBC tumours (Fig. 5n).
MYC expression in HME cells induces EMT
The fact that basal-TNBC and CL-TNBC tumours had similar
expression levels of MYC yet very different expression levels of
CD36, LPL, PDK4 and FABP4 suggested that there are likely other
factors, besides MYC, that direct activation of FAO and lipid
metabolism in CL-TNBC. Furthermore, the lack of correlation
between CD36 expression and Ca2+ transporter expression also
suggested that MYC may not directly modulate lipid metabolism
gene expression. We therefore tested the impact of siRNA-
mediated silencing of MYC on expression of CD36, LPL and PDK4.
Knockdown of MYC repressed expression of LPL and PDK4, but
not CD36, suggesting an alternative regulator of CD36 expression
in MYC HME cells (Supplementary Fig. S6a–d).
We re-examined the RNA sequencing data for potential
modulators of CD36. Elevated fatty acid uptake via CD36 has
been shown to promote EMT in hepatocellular caricinoma49 and
EMT is a defining characteristic of CL-TNBC.29 Interestingly, one of
the top canonical signalling pathways in MYC HME cells was
“Regulation of the EMT pathway” (Fig. 2b; red box). In addition, the
top scoring network from the IPA was “embryonic and organismal
development” (IPA network 1) (Supplementary Fig. S7a). IPA
Network 1 suggested downregulation of E-cadherin (CDH1), Wnt
signalling, and FOXF2 (Supplementary Fig. S7a, black circles).
FOXF2 suppresses EMT in breast cancer and is inversely correlated
with the EMT activator FOXC2.50,51 We used qRT-PCR to confirm
downregulation of FOXF2 and upregulation of FOXC2 (Supple-
mentary Fig. S7b, c). MYC HME cells additionally have high
expression of other EMT inducers, such as ZEB1, ZEB2, and TWIST1
(Supplementary Figs. S6e, S7d, e, and Supplementary Table S1).
We also confirmed downregulation of cell adhesion molecules,
including E-cadherin (CDH1) and claudin 4 (CLDN4), another
defining characteristic of CL-TNBC (Supplementary Fig. S7f, g and
Supplementary Table S1).29 Given the presence of an EMT gene
signature in the MYC HME cells, we hypothesised that EMT
inducers might promote CD36 expression. siRNA-mediated knock-
down of TWIST1, a transcription factor that promotes EMT,
decreased CD36 expression by 50% suggesting that expression
of CD36 in MYC HME cells may be linked to the process of EMT
(Supplementary Fig. S6f, g). The expression of TWIST1 and CD36
highly correlates in CL-TNBC further suggesting these two
molecules may be functionally linked (Supplementary Fig. S6h).
MYC HME cells possess many of the characteristics of
mesenchymal stem-like TNBC
IPA Network 1 also suggested activation of hedgehog (Hh)
signalling (Supplementary Fig. S7a). Hh signalling plays an
important role in embryogenesis, stem-cell renewal, and EMT.52
The glioma-associated oncogene family, which includes GLI2, are
the master transcriptional regulators of Hh signaling.53,54 We
therefore revisited the RNA sequencing data to identify other
genes that contribute to the stem-like phenotype associated with
IPA Network 1. Besides MYC itself, we find upregulation of other
Fig. 5 The fatty acid metabolism gene expression signature of MYC HME cells is highly representative of human claudin-low breast
tumours. a–d Box and whisker plots of fatty acid metabolism gene mRNA expression levels (z-scores) in human breast cancer patient tumours
from the METBRIC database. Tumours were classified based on the PAM50+ claudin-low molecular subtyping of breast cancer as called by the
METABRIC database. Claudin-low, n= 182; Basal, n= 198; HER2, n= 218; Luminal A, n= 673; Luminal B, n= 454; Normal-like, n= 135. Boxes
represent 25th to 75th percentile, whiskers represent min to max, and lines represent medians; p values were determined using an ordinary
one-way ANOVA and Dunnett’s multiple comparison test. e–h Scatter plots of mRNA expression of CD36 against LPL, PDGFRB, PDK4, and
FABP4 in CL-TNBC. Black lines represent linear regression of scatter plots. Spearman correlation r values and p values are reported on graphs. i,
j Kaplan–Meier survival plots of patients with basal-TNBC (j) and CL-TNBC (i). Patients were stratified based on the expression of CD36, LPL,
PDK4, and FABP4 as described in the results; p values were calculated using log-rank test. Hazard ratios (HR) are shown on the plots. k–m Box
and whisker plots of Ca2+ transporter mRNA expression levels (z-scores) in CL-TNBC patient tumours. Tumours were divided in those with
diploid, copy number gains, and amplification of MYC as called by the METBRIC database. Boxes represent 25th to 75th percentile, whiskers
represent min to max, and lines represent medians; p values are reported on the graphs and were determined using an ordinary one-way
ANOVA and Dunnett’s multiple comparison test. n Box and whisker plots of Ca2+ transporter mRNA expression levels (z-scores) in CD36Hi
versus CD36Lo CL-TNBC patient tumours. Boxes represent 25th to 75th percentile, whiskers represent min to max, and lines represent
medians; p values were determined using an unpaired Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N.S.= not significant.
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breast cancer stem cell factors (SOX2, SOX18, THY1, EYA1, GLI2,
SALL1, GLIS1, CXCR4), suggesting that MYC HME cells adopt a
stem-like state (Supplementary Fig. S6i–l and Supplementary
Table S1). Consistent with this result, MYC HME cells had little to
no surface expression of CD24, a surface marker commonly lost on
cancer stem cells (also called tumour initiating cells) (Supplemen-
tary Fig. S6m).55,56 It was reported that the gene expression profile
of CL-TNBC tumours closely clusters with that of so-called
“mesenchymal stem-like” tumours. Mesenchymal stem-like
tumours have a high degree of dedifferentiation, low expression
of claudins, loss of E-cadherin and CD24, and high expression of
genes associated with EMT, including PDGFRB and TWIST.57
Furthermore, PDGFR signalling is known to induce EMT in breast
cancer.58 Altogether, the major transcriptional changes that
occurred in MYC HME cells are also the same changes that occur
in CL-TNBC. The data also suggest that acquisition of an EMT
phenotype in the presence of oncogenic levels of MYC may be
necessary for robust activation of FAO and serve as a distinguish-
ing feature for differentiating CL-TNBC from basal-TNBC.
CL-TNBC cell lines are sensitive to STO-609 and etomoxir
Given the similarities between CL-TNBC and MYC HME cells, we
analysed a panel of TNBC cell lines for expression of p-AMPK, MYC,
CD36, CLDN4, and CLDN7. SUM159PT cells expressed MYC to a
similar level as MYC HME cells, had the highest expression of CD36
and p-AMPK among the TNBC cell lines, and had complete loss of
both claudin 4 and claudin 7 (Fig. 6a–c). Treatment of
SUM159PT cells for two hours with STO-609 led to a decrease in
p-AMPK levels, suggesting that activation of AMPK occurs in a
CAMKK2-dependent manner in SUM159PT cells (Fig. 6d). We also
saw decreased phosphorylation of AMPK in response to STO-609
in two other CL-TNBC cell lines (Supplementary Fig. S8a). We next
tested the ability of PDGF-BB to stimulate FAO in SUM159PT cells
and indeed we observed increased FAO upon treating
SUM159PT cells with PDGF-BB (Fig. 6e). This increase in FAO
could be blocked by the addition of STO-609 or etomoxir. STO-609
also causes an increase in the percentage of SUM159PT cells in S
and G2/M phases of the cell cycle, while etomoxir induced cell
death and an accumulation in S phase (Fig. 6f). In sum, these
results suggest that it may be possible to target FAO in CL-TNBC.
DISCUSSION
Recent studies have highlighted a role for FAO in the growth of
TNBC and suggested that targeting FAO may be beneficial to
TNBC patients.10,13,14,59 The activation of FAO in TNBC has been
linked to overexpression of the oncogene MYC, and previous
studies have shown that inhibition of MYC increases lipid droplet
formation in tumours by causing mitochondrial dysfunction.10,60,61
However, the mechanistic underpinnings by which MYC stimu-
lates FAO in TNBC have remained elusive. We therefore set out to
obtain a deeper understanding of how MYC regulates the import
and oxidation of fatty acids in TNBC.
We found that the activation of FAO is facilitated by
upregulation of LPL and CD36 which mobilise and scavenge fatty
acids. MYC HME cells consumed substantially more carnitine and
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harboured large stores of acetyl-carnitine, a high energy by-
product of FAO. We also found that the overall metabolic flux of
two major mitochondrial fuel sources (i.e. glutamine and fatty
acids) was higher in MYC HME cells compared to TERT HME cells.
CD36 facilitates increased fatty acid uptake and in combination
with PDK4-mediated inhibition of pyruvate dehydrogenase would
promote FAO and inhibit glucose oxidation. Inhibition of glucose
oxidation by PDK4 thus allows CL-TNBC cells to use fatty acids to
fuel mitochondrial acetyl-CoA production which, in turn, might
spare pyruvate and upstream glycolytic intermediates for other
biosynthetic pathways. Such a metabolic transformation would be
highly advantageous to highly proliferative and highly migratory
cancer cells.
Based on our findings, we also propose that Ca2+ release from
internal stores stimulates the activation of CAMKK2 and AMPK to
further promote FAO. We suggest that RTKs such as PDGFRB and
EGFR, both of which are highly expressed in TNBC, activate
intracellular Ca2+ release. However, it is possible that other RTKs or
G-protein coupled receptors may also be involved. MYC may also
further potentiate Ca2+ signalling by repressing expression of
Ca2+ transporters, thereby compromising the ability of the cell to
efficiently export Ca2+ from the cytosol. MYC-induced down-
regulation of the plasma membrane Ca2+ pump ATP2B4 did
impact Ca2+ efflux in B cells and has been linked to proliferation
and differentiation of B cells.62 Our study is the first to show that
Na+/Ca2+ exchanger SLC8A1 is repressed by MYC. Downregula-
tion of the Na+/Ca2+ exchanger SLC8A1 has been associated with
apoptosis evasion in penile carcinomas.63 Our results highlight
that further studies on the impact of ion channels and Ca2+
signalling on cancer metabolism are needed.
Increases in AMPK phosphorylation occur upon induction of
MYC in osteosarcoma cells64 and a recent report suggested that
Ca2+ signalling is involved in MYC-associated activation of NUAK1,
a member of the AMPK-related family of kinases.65 Furthermore,
CAMKK2 is upregulated and phosphorylates AMPK in prostate
cancer, a cancer type that has high MYC expression.66–69 ChIPseq
analysis has shown that MYC binds to the CAMKK2 promoter
region.70 We found that inhibition of CAMKK2 blocked AMPK
phosphorylation, inhibited PDGF-induced FAO, and caused cyto-
static and cytotoxic effects on MYC HME cells and SUM159PT CL-
TNBC cells. The alterations to the cell cycle distribution caused by
STO-609 suggested that there may be other CAMKK2 functions,
outside of stimulating FAO, that control cell cycle. In support of
this concept, siRNA-mediated silencing of CAMKK2 expression in
prostate cancer cells has been shown to increase the percentage
of cells in G1 phase.71
MYC and TERT HME cells have similar proliferation rates (data
not shown), but the cell migration velocity of MYC HME cells was
>10-fold higher than TERT HME cells. We propose that the
heightened metabolic state induced by MYC expression is able to
satisfy the high energy demands of cells that are both highly
migratory and highly proliferative. It is tempting to speculate that
MYC accomplishes this task by “hijacking” Ca2+ signalling as a
means to activate AMPK during otherwise nutrient replete
conditions. By using Ca2+ to activate AMPK, MYC HME cells create
a pseudo starvation state of metabolic stress. AMPK would then
further stimulate multiple metabolic pathways, including FAO. This
boost in energy production would provide an advantage to TNBC
by supporting energy demanding process of cell migration while
also allowing cancer cells to satisfy the biomass and energy
demands of proliferation. Indeed, we found that inhibition of
CD36 or CAMKK2 decreased cell migration.
We envision that migrating cells require a high level of energy
production that CD36 mediated fatty acid uptake and FAO can
provide. Our lipidomic analysis showed that the fatty acids being
taken up by MYC HME cells were also being used for lipid
biosynthesis suggesting that CD36 may also contribute to
membrane biogenesis. The intricacies of membrane remodelling
associated with pseudopod extension and cell surface projections
remains controversial and further studies are needed to elucidate
the exact changes in the types and composition of phospholipids
that reside at leading edges of migrating and invading cells.72
Interestingly, CD36 is an emerging metabolic target and has been
proposed to be crucial for cell migration, invasion, and metastasis
of oral squamous cell carcinoma,73 gastric cancer,74 and ovarian
cancer.75 Our results also agree with a study that suggested that
mobilisation of fatty acids from adipocytes promotes breast
cancer invasion.76 FABP4, which is often co-amplified with MYC
and almost always highly co-expressed with CD36 in breast
cancer, was shown to be critical for ovarian cancer metastasis to
the omental fat pad where it supported fatty acid transport and
FAO.47
Perhaps the most intriguing finding from our study was that CL-
TNBC, specifically, had much higher expression of CD36, LPL,
PDGFRB, FABP4, and PDK4 compared to all other breast cancers,
including basal-TNBC. Given the associations between these fatty
acid metabolism genes and FAO, we suggest that CL-TNBC
patients are likely to experience the greatest benefit from
targeting FAO. There are currently no routine diagnostic tools
for identifying CL breast cancer in the clinic and gene expression
profiling remains the gold standard for molecular subtyping of
TNBC.77 As such, CL breast cancer is often more broadly
categorised as TNBC in the clinic and targeted therapies are
non-existent for patients with CL breast cancer.78 Efforts are
already underway to better diagnose CL breast cancer in the clinic
and it will be interesting to see the potential of fatty acid
metabolism genes to serve as markers of CL breast cancer.
Our research also supports a rationale for inhibiting one or more
of the alternative FAO targets identified in our study, such
CAMKK2 and CD36. Targeting CAMKK2 in combination with CD36
could impact FAO at two different points, and the secondary
functions of these targets in cell cycle regulation and membrane
biogenesis, respectively, may offer further benefit as well. Overall,
our study provides a deeper understanding of the link between
TNBC and FAO and shows that MYC promotes a multigenic
program that drastically changes the behaviour and metabolism
of breast cells.
Our findings have the potential to impact breast cancer
treatment beyond CL-TNBC. For instance, it has been suggested
that regardless of the initial breast cancer subtype, the cancer cells
remaining after chemotherapy or endocrine therapy (i.e. relapsed
tumours) largely adopt CL breast cancer characteristics.79 Further-
more, it is interesting to note that many mouse models of breast
cancer eventually adopt CL breast cancer characteristics.80,81 An
example is that inactivation of MYC expression in breast tumour
bearing mice leads to tumour regression, but many of these
tumours eventually recur.81 Unsupervised gene clustering analysis
of these recurrent breast tumours indicated enrichment for a CL
gene signature, which was completely absent in the primary
tumours. Likewise, ~20% of the tumours that emerge in MMTV-
MYC model adopt an EMT/squamous tumour phenotype that is
highly similar to claudin-low breast cancer.80 This phenomenon,
however, is not exclusive to MYC-driven models. Recurrent Neu-
induced (i.e. HER2+) mammary tumours also display an EMT
phenotype.82 There is, therefore, a crucial need to identify novel
therapeutic opportunities in CL breast cancer, not only because it
is a poorly understood molecular subtype, but also because its
gene expression patterns are highly representative of a large
proportion of resistant and recurrent tumours in human breast
cancer patients.
Our bioinformatic analyses revealed striking similarities
between these aforementioned mouse studies and our MYC
HME cells. MYC HME cells adopted a CL-TNBC gene signature, but
interestingly many of the EMT associated genes were not directly
regulated by MYC (i.e. CD36, ZEB1, ZEB2, PDGFRB, etc). It is
becoming clearly evident that cancer cells can evolve and thrive
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independent of the oncogene-initiating event (i.e. MYC activa-
tion).81,83 Our current hypothesis is that the MYC establishes a
background from which highly transformed and resistant cells
emerge. The exact mechanism by which MYC creates this
conducive cellular state remains unknown, but may involve
long-term dysregulation of Ca2+ signaling,62 alterations in
microRNA expression,84 or epigenetic reprogramming.85 Amplifi-
cation of Ca2+ signalling through downregulation of Ca2+
transporters has been noted as a potential tumour promoting
mechanism in other cancer types, including the Eμ-myc model of
lymphoma.62,63
Overall, using our cell-based model, we were able to uncover
novel targets within the fatty acid metabolism pathway that are
prevalent in CL breast cancer and significantly correlate with poor
patient survival. We predict that the uptake and oxidation of fatty
acids is a crucial metabolic process for cell migration and a driving
force behind the prevalence of a fatty acid metabolism gene
signature in CL-TNBC. Future studies will examine the therapeutic
potential of targeting fatty acid metabolism in CL-TNBC and how
high-fat diets and obesity may influence fatty acid metabolism
and tumour progression. There is also much to be learned
concerning the cross talk between growth factor signalling, Ca2+
signalling, and metabolism. It is well known that many mitochon-
drial dehydrogenases and transporters contain Ca2+ binding sites
and EF-hand motifs; however, the role of amplified Ca2+ signalling
in mitochondrial function in cancer is largely unexplored.
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